Asset Management One Co. Ltd. Reduces Stock Position in DaVita Inc. $DVA

Asset Management One Co. Ltd. lowered its stake in DaVita Inc. (NYSE:DVA) by 10.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,036 shares of the company’s stock after selling 2,027 shares during the quarter. Asset Management One Co. Ltd.’s holdings in DaVita were worth $2,569,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DVA. Doma Perpetual Capital Management LLC boosted its holdings in DaVita by 172.3% in the first quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after purchasing an additional 182,476 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of DaVita during the 2nd quarter worth $21,554,000. Northern Trust Corp boosted its stake in shares of DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after acquiring an additional 149,858 shares during the last quarter. Nuveen LLC purchased a new position in shares of DaVita during the 1st quarter worth $20,218,000. Finally, Amundi boosted its stake in shares of DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after acquiring an additional 71,304 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 2.6%

DaVita stock opened at $126.25 on Thursday. The company’s 50-day moving average price is $131.59 and its 200-day moving average price is $137.01. DaVita Inc. has a twelve month low of $122.93 and a twelve month high of $179.60. The company has a market cap of $9.03 billion, a PE ratio of 12.41, a price-to-earnings-growth ratio of 0.93 and a beta of 1.13.

DaVita (NYSE:DVA) last posted its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.29 by ($0.78). DaVita had a return on equity of 369.39% and a net margin of 6.35%.During the same quarter in the prior year, the company earned $2.59 earnings per share. The business’s revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the topic of several analyst reports. Barclays dropped their price target on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 9th. Truist Financial set a $140.00 price target on shares of DaVita in a research note on Tuesday, October 14th. Bank of America decreased their price objective on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 10th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $153.25.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.